[SCHEDULE 13G/A] Autonomix Medical, Inc. SEC Filing

Rhea-AI Filing Summary

Autonomix Medical, Inc. received an amended Schedule 13G disclosing that BioStar Ventures III entities beneficially own 175,216 shares of common stock, representing 4.3% of the outstanding common stock on a fully adjusted basis. BioStar Ventures III, L.P. directly holds 120,816 shares and warrants exercisable for 54,400 shares; BioStar Ventures III, L.L.C. is the general partner and shares voting and dispositive power over the same 175,216 shares. The filing states the ownership calculation is based on 4,022,625 shares outstanding adjusted to include shares issuable upon exercise of the warrants. The Reporting Persons disclaim being a group and indicate this position constitutes 5% or less of the class.

Positive

• Transparent ownership disclosure of aggregate position and warrant exposure (175,216 shares; 54,400 warrants)
• Breakdown of direct vs. shared voting and dispositive power clarifies control relationships between the partnership and its general partner
• Position quantified as 4.3% of class based on disclosed share count, enabling investor assessment of stake size

Negative

• Stake remains under 5%, indicating no reported control or activist intent under Schedule 13G thresholds
• Warrant exposure introduces potential dilution (54,400 shares exercisable) though timing and exercise conditions are not provided in this filing

Insights

Financial Analyst

TL;DR BioStar holds a 4.3% economic interest including warrants, a disclosure of modest passive ownership without control.

The Schedule 13G/A reports an aggregate beneficial ownership of 175,216 shares, including warrants for 54,400 shares, against a stated base of 4,022,625 shares outstanding. From an investor-impact perspective this size position is below common material thresholds for activism or control and is consistent with passive investment reporting. The clear breakdown between direct shareholdings and warrant exposure helps quantify potential dilution and voting power if warrants are exercised.

Corporate Governance Expert

TL;DR Ownership disclosure shows shared voting via the general partner but does not indicate a control position.

The filing clarifies that BioStar Ventures III, L.L.C. serves as general partner and shares voting and dispositive power over the securities held by the partnership. The Reporting Persons expressly disclaim group status and report ownership below 5% of the class, implying routine passive holding under the Schedule 13G framework rather than an active governance stake. This limits immediate corporate governance implications from this disclosure alone.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

Autonomix Medical, Inc.

(Name of Issuer)

Common Stock, $0.001 par value per share

(Title of Class of Securities)

05330T205

(CUSIP Number)

06/30/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 05330T205

1

Names of Reporting Persons

BioStar Ventures III, L.P.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 175,216.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 175,216.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

175,216.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.3 %

12

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13G

CUSIP No. 05330T205

1

Names of Reporting Persons

BioStar Ventures III, L.L.C.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 175,216.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 175,216.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

175,216.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.3 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Autonomix Medical, Inc.
(b)	Address of issuer's principal executive offices: 21 Waterway Avenue, Suite 300, The Woodlands, TX, 77380.
Item 2.
(a)	Name of person filing: The names of the persons filing this report (collectively, the "Reporting Persons") are: BioStar Ventures III, L.P. ("BioStar III") BioStar Ventures III, L.L.C. ("BioStar III GP") The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13G.
(b)	Address or principal business office or, if none, residence: 206 Bridge Street, Charlevoix, MI 49720
(c)	Citizenship: BioStar III Delaware BioStar III GP Delaware
(d)	Title of class of securities: Common Stock, $0.001 par value per share
(e)	CUSIP No.: 05330T205
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: Row 9 of each Reporting Person's cover page to this Schedule 13G sets forth the aggregate number of securities of the Issuer beneficially owned by such Reporting Person as of June 30, 2025 and is incorporated by reference. BioStar III directly holds (i) 120,816 shares of common stock and (ii) warrants (the "Warrants") exercisable for up to 54,400 shares of common stock. BioStar III GP is the general partner of BioStar III and shares voting and dispositive power over the securities held by BioStar III.
(b)	Percent of class: Row 11 of each Reporting Person's cover page to this Schedule 13G sets forth the percentage of the common stock of the Issuer beneficially owned by such Reporting Person as of June 30, 2025 and is incorporated by reference. The percentage set forth in row 11 is based upon 4,022,625 shares of common stock outstanding as of June 30, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the "SEC") on August 13, 2025, adjusted in accordance with rules of the SEC to include shares issuable upon exercise of the Warrants.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: Row 5 of each Reporting Person's cover page to this Schedule 13G sets forth the sole power to vote or to direct the vote of securities of the Issuer beneficially owned by such Reporting Person as of June 30, 2025 and is incorporated by reference.
	(ii) Shared power to vote or to direct the vote: Row 6 of each Reporting Person's cover page to this Schedule 13G sets forth the shared power to vote or to direct the vote of securities of the Issuer beneficially owned by such Reporting Person as of June 30, 2025 and is incorporated by reference.
	(iii) Sole power to dispose or to direct the disposition of: Row 7 of each Reporting Person's cover page to this Schedule 13G sets forth the sole power to dispose or to direct the disposition of securities of the Issuer beneficially owned by such Reporting Person as of June 30, 2025 and is incorporated by reference.
	(iv) Shared power to dispose or to direct the disposition of: Row 8 of each Reporting Person's cover page to this Schedule 13G sets forth the shared power to dispose or to direct the disposition of securities of the Issuer beneficially owned by such Reporting Person as of June 30, 2025 and is incorporated by reference.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.	Certifications:
	Not Applicable

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

BioStar Ventures III, L.P.

Signature:	/s/ Louis Cannon, MD
Name/Title:	By BioStar Ventures III, L.L.C., its General Partner, By Louis Cannon, MD, Senior Managing Director
Date:	08/14/2025

BioStar Ventures III, L.L.C.

Signature:	/s/ Louis Cannon, MD
Name/Title:	By Louis Cannon, MD, Senior Managing Director
Date:	08/14/2025

Exhibit Information

Exhibit 99.1 Joint Filing Agreement

FAQ

How many shares of AMIX does BioStar Ventures III report owning?

The Reporting Persons disclose beneficial ownership of 175,216 shares of AMIX common stock inclusive of warrants.

What percentage of Autonomix Medical (AMIX) does BioStar Ventures III own?

The filing reports ownership equal to 4.3% of the common stock on a fully adjusted basis.

How many warrants are included in BioStar's reported position in AMIX?

BioStar III directly holds warrants exercisable for 54,400 shares, included in the 175,216 total.

Does this Schedule 13G/A indicate BioStar is part of an investor group for AMIX?

No; the Reporting Persons expressly disclaim status as a group in the filing.

Who holds voting and dispositive power over the reported AMIX shares?

BioStar Ventures III, L.L.C. is the general partner and shares voting and dispositive power over the securities held by BioStar Ventures III, L.P.